The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113

In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Ikuhiro, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ueno, Makoto, Ikeda, Masafumi, Okano, Naohiro, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Sekimoto, Mitsugu, Tobimatsu, Kazutoshi, Yamaguchi, Hironori, Nishina, Tomohiro, Shirakawa, Hirofumi, Kojima, Yasushi, Oono, Takamasa, Kawamoto, Yasuyuki, Furukawa, Masayuki, Iwai, Tomohisa, Sudo, Kentaro, Okamura, Keiya, Yamashita, Tatsuya, Kato, Naoya, Shioji, Kazuhiko, Shimizu, Kyouko, Nakagohri, Toshio, Kamata, Ken, Ishii, Hiroshi, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770671/
https://www.ncbi.nlm.nih.gov/pubmed/35046457
http://dx.doi.org/10.1038/s41598-021-04550-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770671/
https://www.ncbi.nlm.nih.gov/pubmed/35046457
http://dx.doi.org/10.1038/s41598-021-04550-8

Ejemplares similares